News Briefs Ganymed Raises Series C By PE Hub Staff - 18 April 2007 Share A- A+ 100% GANYMED Pharmaceuticals AG, a Mainz, Germany-based developer of cancer antibodies, has raised EUR 33.7 million in Series C funding. VI Partners led the deal, and was joined by Future Capital, Ingro Finanz, Landesbank Baden-W Share this:TwitterLinkedIn